AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7665644 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious mononucleosis (IM) patients
Number of subjects: 68
Study 7665644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal infectious mononucleosis (IM) patients
Number of subjects: 68
Study 7665644 — intervention group
Group type: EXPERIMENTAL
Intervention: EBVAHS patients (acute phase)
Number of subjects: 68
Study 7665644 — intervention group
Group type: EXPERIMENTAL
Intervention: EBVAHS patients (convalescent phase)
Number of subjects: 68
Study 7665644 — intervention group
Group type: EXPERIMENTAL
Intervention: CAEBV patients
Number of subjects: 68
Study 7665644 — intervention group
Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 68
Study 2527534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 16
Study 2527534 — intervention group
Group type: COMPARATOR
Intervention: Food
Number of subjects: 16
Study 184377 — intervention group
Group type: EXPERIMENTAL
Intervention: N 041 (essential phospholipids in combination with Clofibrate)
Number of subjects: 96
Study 184377 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate alone
Number of subjects: 96
Study 30738219 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day CBT Stress management programme (DISCOVER) with telephone follow-up
Number of subjects: 155
Study 30738219 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 155
Study 28352163 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EG) - balance and strength training for 60 min, three times/week for 6 months
Number of subjects: 65
Study 28352163 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no modification of usual habits
Number of subjects: 65
Study 25466509 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus aflibercept
Number of subjects: 1226
Study 25466509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1226
Study 23021878 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (4 to 8 subcutaneous doses, n = 16)
Number of subjects: 24
Study 23021878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study 21689393 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive early intervention services for 18 months
Number of subjects: 150
Study 21689393 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 19624838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cineole 200 mg, 3 times daily for 6 months
Number of subjects: 242
Study 19624838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 17114212 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (10 sessions over five weeks)
Number of subjects: 135
Study 14989750 — intervention group
Group type: EXPERIMENTAL
Intervention: APC Clarity brackets
Number of subjects: 20
Study 14989750 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Clarity brackets with Transbond XT
Number of subjects: 20
Study 11788018 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cystoscopy
Number of subjects: 288
Study 9140801 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg/HCTZ 12.5 mg
Number of subjects: 140
Study 9140801 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100 mg/HCTZ 12.5 mg
Number of subjects: 140
Study 7475401 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed parameters to some providers
Number of subjects: 0
Study 7475401 — intervention group
Group type: COMPARATOR
Intervention: Not revealing parameters to other providers (Control)
Number of subjects: 0
Study 2142246 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg toremifene daily
Number of subjects: 0
Study 2142246 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg toremifene daily
Number of subjects: 0
Study 2142246 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH functional test
Number of subjects: 0
Study 6766049 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet by a needle catheter jejunostomy
Number of subjects: 26
Study 6766049 — intervention group
Group type: COMPARATOR
Intervention: Intravenous control
Number of subjects: 26
Study 30558968 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated gel dressing
Number of subjects: 115
Study 30558968 — intervention group
Group type: COMPARATOR
Intervention: Transparent polyurethane dressing
Number of subjects: 115
Study 27189071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) to the right cerebellar hemisphere
Number of subjects: 14
Study 27189071 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified in the abstract)
Number of subjects: 14
Study 26506580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) delivered over 14 sessions for 4 months
Number of subjects: 30
Study 26506580 — intervention group
Group type: COMPARATOR
Intervention: Control condition consisting of written psycho-education materials and weekly telephone monitoring
Number of subjects: 30
Study 23399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 952
Study 23399518 — intervention group
Group type: COMPARATOR
Intervention: Mail follow-up
Number of subjects: 952
Study 21846154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (titrated to 300 mg after 6 weeks)
Number of subjects: 363
Study 21846154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 19542517 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SMS (one weekly SMS feedback)
Number of subjects: 174
Study 19542517 — intervention group
Group type: EXPERIMENTAL
Intervention: 3SMS (three weekly SMS feedbacks)
Number of subjects: 174
Study 19542517 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without intervention)
Number of subjects: 174
Study 17287682 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 17287682 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI (immediate planned PCI after i.v. thrombolytic therapy)
Number of subjects: 0
Study 17287682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI after failed thrombolysis
Number of subjects: 0
Study 17287682 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI
Number of subjects: 0
Study 17287682 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser thrombectomy before PCI
Number of subjects: 0
Study 15169865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 26
Study 15169865 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 26
Study 11527067 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi therapy (QT)
Number of subjects: 40
Study 11527067 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 8840055 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg esmolol
Number of subjects: 45
Study 8840055 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg esmolol
Number of subjects: 45
Study 8840055 — intervention group
Group type: COMPARATOR
Intervention: 20 ml normal saline (Control Group P)
Number of subjects: 45
Study 1299974 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU as a short i.v. perfusion or as a continuous perfusion over 3 to 5 days
Number of subjects: 1097
Study 1299974 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU as a continuous perfusion
Number of subjects: 1097
Study 1299974 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with 5-FU
Number of subjects: 1097
Study 1299974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse cardiac effects
Number of subjects: 1097
Study 6391417 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGBF) plus physiotherapy (PT)
Number of subjects: 0
Study 6391417 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone
Number of subjects: 0
Study 31072566 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 27395
Study 31072566 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 27395
Study 31072566 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg plus aspirin
Number of subjects: 27395
Study 28825348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT) - 3 times/week for 20 minutes, including five 3-minute exercise intervals at 80% of peak oxygen uptake (VO2-peak)
Number of subjects: 60
Study 28825348 — intervention group
Group type: COMPARATOR
Intervention: Control training (CT) - continuously 5 times/week for 30 minutes/session at 65% of VO2-peak
Number of subjects: 60
Study 28825348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT)
Number of subjects: 60
Study 26831333 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% linalool inhalation
Number of subjects: 37
Study 26831333 — intervention group
Group type: COMPARATOR
Intervention: Carrier oil (control)
Number of subjects: 37
Study 25233668 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric combined with musical treatment (group A)
Number of subjects: 126
Study 25233668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (group B)
Number of subjects: 126
Study 25233668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch tablet, group C)
Number of subjects: 126
Study 22061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain rye porridge breakfast
Number of subjects: 24
Study 22061429 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread breakfast
Number of subjects: 24
Study 22061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both breakfasts
Number of subjects: 24
Study 22061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 24
Study 19095665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook catheter
Number of subjects: 1155
Study 19095665 — intervention group
Group type: COMPARATOR
Intervention: Frydman catheter
Number of subjects: 1155
Study 19095665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 1)
Number of subjects: 1155
Study 19095665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 2)
Number of subjects: 1155
Study 19095665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 3)
Number of subjects: 1155
Study 17925627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual therapy group (n=47)
Number of subjects: 92
Study 17925627 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 92
Study 15756442 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2, FA 20 mg/m2 followed by 5‐FU 500 mg/m2 bolus, weekly for 4 weeks (arm A)
Number of subjects: 149
Study 15756442 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2 alternating with FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day for 5 days (arm B)
Number of subjects: 149
Study 15756442 — intervention group
Group type: COMPARATOR
Intervention: FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day over 5 days every 4 weeks (arm C, Mayo Clinic regimen)
Number of subjects: 149
Study 12077765 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MMP-2 levels in POBA patients
Number of subjects: 36
Study 12077765 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MMP-1 levels in POBA patients
Number of subjects: 36
Study 12077765 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TIMP-1 and TIMP-2 levels in POBA patients
Number of subjects: 36
Study 10211526 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal inserted stapler
Number of subjects: 58
Study 10211526 — intervention group
Group type: COMPARATOR
Intervention: Biofragmentable anastomotic ring
Number of subjects: 58
Study 10211526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 8559001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fordtran solution (polyethylene glycol solution)
Number of subjects: 100
Study 8559001 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution (whole-gut lavage)
Number of subjects: 100
Study 2341994 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling programme (education and psychological support) in addition to routine care
Number of subjects: 60
Study 2341994 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 60
Study 7018164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose given to females with treated partners
Number of subjects: 137
Study 7018164 — intervention group
Group type: COMPARATOR
Intervention: Placebo given to females with untreated partners
Number of subjects: 137
Study 7018164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose
Number of subjects: 137
Study 7018164 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 137
Study 31526071 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 42
Study 31526071 — intervention group
Group type: COMPARATOR
Intervention: Control (mock infiltration)
Number of subjects: 42
Study 27768806 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Smart
Number of subjects: 1316
Study 27768806 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Smart
Number of subjects: 1316
Study 27768806 — intervention group
Group type: EXPERIMENTAL
Intervention: HELPP
Number of subjects: 1316
Study 27768806 — intervention group
Group type: COMPARATOR
Intervention: Control (usual school class)
Number of subjects: 1316
Study 25425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic infants
Number of subjects: 1316
Study 25425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuators
Number of subjects: 1316
Study 25425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Max PaCO2 increase (per 10 mm Hg)
Number of subjects: 1316
Study 25425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Max PaCO2
Number of subjects: 1316
Study 25605211 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNRH)
Number of subjects: 65
Study 25605211 — intervention group
Group type: COMPARATOR
Intervention: Classical laparoscopic radical hysterectomy (LRH)
Number of subjects: 65
Study 23226223 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI+OMT
Number of subjects: 0
Study 23226223 — intervention group
Group type: COMPARATOR
Intervention: OMT
Number of subjects: 0
Study 19036903 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (260 mg/m² q3wk)
Number of subjects: 24
Study 19036903 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (100 mg/m² q3wk)
Number of subjects: 24
Study 19036903 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel (175 mg/m² q3wk)
Number of subjects: 24
Study 17279848 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher power groups
Number of subjects: 0
Study 17279848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower power groups
Number of subjects: 0
Study 17279848 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit and implicit measures of group attraction
Number of subjects: 0
Study 15469651 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (4.9 g DHA/d)
Number of subjects: 42
Study 15469651 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich oil (4.8 g EPA/d)
Number of subjects: 42
Study 15469651 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 42
Study 11781674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnamese foods (three rices, three noodle products, three sweet foods)
Number of subjects: 12
Study 11781674 — intervention group
Group type: COMPARATOR
Intervention: Reference food (glucose sugar)
Number of subjects: 12
Study 11781674 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GI values between racial groups
Number of subjects: 12
Study 9757148 — intervention group
Group type: EXPERIMENTAL
Intervention: Supernatant fraction (naringin and 6',7'-dihydroxybergamottin)
Number of subjects: 12
Study 9757148 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate fraction
Number of subjects: 12
Study 9757148 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 9757148 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 7821886 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 46
Study 7821886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3555650 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with chlorambucil and prednisone (CP)
Number of subjects: 108
Study 3555650 — intervention group
Group type: COMPARATOR
Intervention: Fractionated total body irradiation (TBI)
Number of subjects: 108
Study 29619838 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised endurance/resistance training (ET)
Number of subjects: 62
Study 29619838 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62
Study 29619838 — intervention group
Group type: EXPERIMENTAL
Intervention: L-homoarginine (L-hArg) levels
Number of subjects: 62
Study 29115868 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for post-concussive symptoms
Number of subjects: 49
Study 25122097 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented therapy with personalized resistance (TOT_ST group)
Number of subjects: 20
Study 25122097 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented therapy without load (TOT group)
Number of subjects: 20
Study 22921881 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Number of subjects: 18
Study 22921881 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin rechallenge
Number of subjects: 18
Study 20804498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime (700 mg)
Number of subjects: 0
Study 20804498 — intervention group
Group type: COMPARATOR
Intervention: Pralidoxime (350 mg), Atropine (2 mg), Avizafone (20 mg)
Number of subjects: 0
Study 17591020 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon-alpha2b
Number of subjects: 8
Study 15705641 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h
Number of subjects: 54
Study 15705641 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg every 12 h
Number of subjects: 54
Study 15705641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 54
Study 12010590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy preload (2513 kJ)
Number of subjects: 23
Study 12010590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy preload (1008 kJ)
Number of subjects: 23
Study 12010590 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers
Number of subjects: 23
Study 12010590 — intervention group
Group type: COMPARATOR
Intervention: Self-ratings of hunger
Number of subjects: 23
Study 9700174 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 39
Study 9700174 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 39
Study 7637721 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg daily)
Number of subjects: 123
Study 7637721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (3000 mg daily)
Number of subjects: 123
Study 2692819 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg orally, twice daily)
Number of subjects: 33
Study 2692819 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (375 mg orally, twice daily)
Number of subjects: 33
Study 832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin, total dose of 4 g (2g/4h)
Number of subjects: 70
Study 832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin, single dose of 4 g (2 g in each buttock)
Number of subjects: 70
Study 832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin, 2g/8h for 2 days
Number of subjects: 70
Study 832528 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 4 g (control for failures)
Number of subjects: 70
Study 30846834 — intervention group
Group type: EXPERIMENTAL
Intervention: light-intensity treadmill walking
Number of subjects: 8
Study 30846834 — intervention group
Group type: EXPERIMENTAL
Intervention: moderate-intensity treadmill walking
Number of subjects: 8
Study 30846834 — intervention group
Group type: COMPARATOR
Intervention: prolonged uninterrupted sitting
Number of subjects: 8
Study 29719302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg orally daily)
Number of subjects: 90
Study 29719302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Erlotinib
Number of subjects: 90
Study 29719302 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 90
Study 29719302 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 90
Study 29719302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Erlotinib among Child‐Pugh class A patients
Number of subjects: 90
Study 29719302 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib among Child‐Pugh class A patients
Number of subjects: 90
Study 27102490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (SVL)
Number of subjects: 109
Study 27102490 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders (CPiB)
Number of subjects: 109
Study 27102490 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EAT progression between SVL and CPiB
Number of subjects: 109
Study 23354743 — intervention group
Group type: COMPARATOR
Intervention: Control + Clearfil SE Bond (SE)
Number of subjects: 96
Study 23354743 — intervention group
Group type: COMPARATOR
Intervention: Control + Single Bond (SB)
Number of subjects: 96
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: diamond bur (DB) + SE
Number of subjects: 96
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: DB + SB
Number of subjects: 96
Study 23354743 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (2.94 μm, 60 mJ, 2 Hz, 0.12 W, 19.3 J/cm(2)) + SE
Number of subjects: 96